Allos Therapeutics, Inc. Announces Interim Results from Phase 1 Combination Study of FOLOTYN® and Bexarotene Demonstrate Activity in Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma
WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ:ALTH) today reported interim results from the Company’s ongoing Phase 1 combination study of FOLOTYN® (pralatrexate injection) and bexarotene in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). The combination treatments demonstrated encouraging activity in heavily pre-treated patients (median of 3 prior systemic regimens). Data were presented during an oral presentation at the Fourth Annual T-cell Lymphoma Forum, on January 28 in San Francisco, CA.